Drugs / Tc99m sestamibi

Trials 3 · a red edge is where a trial was stopped

20122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT05042687 Dec 2021 → Dec 2027 expected breast cancer M.D. Anderson Cancer Center Recruiting No outcome recorded
NCT02324387 Jun 2015 → Mar 2028 expected breast cancer M.D. Anderson Cancer Center Active not recruiting No outcome recorded
NCT01499654 Oct 2011 → Dec 2014 ischemic disease, myocardial infarction Edwin Wu Terminated No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01019486 Background Nov 2009 → Dec 2011 coronary artery disorder, type 1 diabetes mellitus University of Colorado, Denver Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Tc99m sestamibi “Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed...” NCT01019486
3

“a small catheter (tube) will be placed in a vein in the subject's arm to administer the radioactive imaging agent, Tc-99m sestamibi.” NCT01499654

NCT05042687

NCT02324387

Known as Cardiolite (sestamibi) Cardiolite (sestamibi)NCT01019486
Known as technetium (Tc-99m) sestamibi, Cardiolite technetium (Tc-99m) sestamibi, CardioliteNCT01499654
Modality Diagnostic / imaging agent “Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected” NCT01019486
Route Intravenous “a small catheter (tube) will be placed in a vein in the subject's arm to administer the radioactive imaging agent, Tc-99m sestamibi.” NCT01499654